Clinical trial
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and…
NCT00113581 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00113581 |
|---|---|
| Title | Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer |
| Official title | A Phase I Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Three Doses of Humanised EGFR Antibody EMD 72000 in Combination With ECX in Patients With Advanced Oesophagogastric Adenocarcinoma |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | EMD 72000 (matuzumab) + ECX |
| Enrollment | 26 |
| Start date | Oct 1, 2002 |
| Primary completion | May 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Jun 10, 2005 |
| Last update posted | Feb 19, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: